AbCellera Biologics (ABCL) vs Edgewise Therapeutics (EWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed AbCellera Biologics (ABCL) over the past year, gaining 161.4% versus a gain of 122.4%. Over five years, EWTX leads with a +123.1% price change compared with -17.4% for ABCL. Edgewise Therapeutics is the larger company by market cap ($4.30 billion vs $4.16 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | EWTX |
|---|---|---|
| Share price | $12.83 | $39.57 |
| Market cap | $4.16B | $4.30B |
| 1-day change | -2.43% | -1.12% |
| YTD return | +275.15% | +59.46% |
| 1-year return | +122.36% | +161.36% |
| 5-year return | -17.39% | +123.06% |
| EPS (TTM) | $-0.54 | $-1.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | — |
| Revenue growth (YoY) | +160.56% | — |
| Net income (latest FY) | $-146.41M | $-167.79M |
| Operating margin | -288.98% | — |
| Net margin | -194.88% | — |
| 52-week high | $15.02 | $48.51 |
| 52-week low | $2.75 | $14.25 |
| Distance from 52-week high | -14.55% | -18.43% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +30.16% | +32.98% |
| Average volume | 6.74M | 1.35M |
| Shares outstanding | 324.05M | 108.60M |
| Employees | 562 | 127 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed ABCL by 39.0 percentage points over the past year.
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
ABCL vs EWTX FAQ
Which is bigger, AbCellera Biologics or Edgewise Therapeutics?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.30B compared with $4.16B for AbCellera Biologics (ABCL).
Which stock has performed better over the past year, ABCL or EWTX?
EWTX returned +161.36% over the past 12 months, compared with +122.36% for ABCL (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Edgewise Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.